Dementia with Lewy Bodies (DLB), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), and [Alzheimer's Disease](/diseases/alzheimers-disease) (AD) are the three most common neurodegenerative disorders causing cognitive decline in aging populations. While each has a distinct primary pathology, they share substantial clinical, neurochemical, and mechanistic overlap that has critical implications for diagnosis, treatment, and biomarker development.
The comparison below examines these three diseases across eight key dimensions, revealing both their distinct signatures and the shared pathways that offer therapeutic targets applicable across multiple conditions.
Dementia with Lewy Bodies (DLB), [Parkinson's Disease](/diseases/parkinsons-disease) (PD), and [Alzheimer's Disease](/diseases/alzheimers-disease) (AD) are the three most common neurodegenerative disorders causing cognitive decline in aging populations. While each has a distinct primary pathology, they share substantial clinical, neurochemical, and mechanistic overlap that has critical implications for diagnosis, treatment, and biomarker development.
The comparison below examines these three diseases across eight key dimensions, revealing both their distinct signatures and the shared pathways that offer therapeutic targets applicable across multiple conditions.
| Feature | DLB | Parkinson's Disease | Alzheimer's Disease |
|---------|-----|---------------------|---------------------|
| Primary protein | [Alpha-synuclein](/proteins/alpha-synuclein) | [Alpha-synuclein](/proteins/alpha-synuclein) | [Amyloid-beta](/proteins/amyloid-beta) + [Tau](/proteins/tau) |
| Key inclusions | Cortical Lewy bodies, Lewy neurites | Brainstem Lewy bodies, Lewy neurites | Amyloid plaques, neurofibrillary tangles |
| Inclusion location | Cortex, limbic, brainstem | Substantia nigra, cortex (in PDD) | Hippocampus, cortex |
| Co-pathology rate | ~50-60% have concurrent AD pathology[@donovan2024] | ~40-60% have AD co-pathology[@aarsland2021] | ~20-30% have alpha-synuclein co-pathology |
| Staging pattern | Diffuse cortical early; less brainstem-predominant[@ferman2024] | Braak staging: brainstem → limbic → cortical | Braak NFT stages; amyloid follows separate pattern |
The boundary between these diseases is blurred by frequent co-pathology[@jellinger2023]:
| Feature | DLB | Parkinson's Disease | Alzheimer's Disease |
|---------|-----|---------------------|---------------------|
| Nigrostriatal dopamine loss | Moderate (less than PD) | Severe | Mild or absent |
| Motor response to levodopa | Variable; often modest | Good to excellent | Not applicable |
| Dopaminergic cell loss | Substantia nigra pars compacta | Marked, progressive loss | Limited |
| Striatal dopamine depletion | 50-70% | 70-90% | Minimal |
DLB has significant dopaminergic loss in the substantia nigra, causing parkinsonism, but the depletion is generally less severe than in PD[@dupre2024]. This correlates with the often less robust response to levodopa in DLB compared to PD.
| Feature | DLB | Parkinson's Disease | Alzheimer's Disease |
|---------|-----|---------------------|---------------------|
| Nucleus basalis of Meynert loss | Severe (80-90%)[@bohnen2023] | Moderate (30-50%) | Moderate (30-50%) |
| Cortical cholinergic denervation | Severe | Moderate | Moderate |
| Cholinesterase inhibitor response | Often robust | Modest | Moderate |
| Pedunculopontine nucleus | Affected (causes RBD, gait dysfunction) | Affected (causes gait dysfunction) | Less affected |
The cholinergic deficit in DLB is the most severe of all neurodegenerative dementias[@bohnen2023]. This explains:
| Neurotransmitter | DLB | PD | AD |
|-----------------|-----|----|----|
| Noradrenergic (locus coeruleus) | Severe loss | Moderate loss | Early but less severe |
| Serotonergic (raphe) | Affected | Affected | Affected |
| GABAergic | Affected | Loss of GABAergic interneurons in substantia nigra | Synaptic GABA loss |
| Glutamatergic | Thalamic relay disruption | Cortical glutamate dysregulation | Cortical glutamate excitotoxicity |
The noradrenergic deficit is particularly prominent in DLB, contributing to the characteristic attention fluctuations[@ffytche2024]. The locus coeruleus is affected early by alpha-synuclein pathology in both DLB and PD, but the additional cholinergic loss in DLB creates a unique combination of arousal system failure.
| Feature | DLB | Parkinson's Disease | Alzheimer's Disease |
|---------|-----|---------------------|---------------------|
| Overall severity | Early, prominent | Mild-moderate, develops later | Late, less prominent |
| Orthostatic hypotension | Common (40-60%)[@orimo2024] | Common (30-50%) | Uncommon |
| Supine hypertension | Common (baroreflex failure) | Present | Uncommon |
| Constipation | Very common (often predates diagnosis by decades) | Very common | Less common |
| Urinary dysfunction | Common (urgency, retention) | Common | Less common |
| Anhidrosis | Present | Present | Rare |
| Syncope | Common | Occasional | Rare |
| Cardiac sympathetic denervation | Severe (MIBG scan markedly reduced) | Present | Absent or mild |
| Mechanism | Peripheral and central alpha-synuclein | Peripheral and central alpha-synuclein | AD pathology less affects autonomic centers |
DLB and PD share a common autonomic phenotype driven by alpha-synuclein pathology in peripheral postganglionic sympathetic neurons, enteric nervous system, and central autonomic centers[@orimo2024]. The loss of cardiac sympathetic innervation (detected by MIBG scintigraphy or PET imaging of sympathetic nerves) is a particularly useful biomarker distinguishing DLB from AD, and can also help differentiate PD from other parkinsonisms.
| Modality | DLB | PD | AD |
|----------|-----|----|----|
| MIBG myocardial scintigraphy | Markedly reduced uptake | Reduced uptake | Normal or near-normal |
| 6-[18F]fluorodopamine PET | Reduced | Reduced | Normal |
| Cardiac sympathetic density | Severely reduced | Reduced | Preserved |
This makes cardiac autonomic imaging a key tool in the differential diagnosis between DLB and AD, and between Lewy body diseases and other dementias.
| Domain | DLB | Parkinson's Disease | Alzheimer's Disease |
|--------|-----|---------------------|---------------------|
| Onset pattern | Attention/executive deficits first | Executive dysfunction early; motor precedes | Memory encoding deficit first |
| Fluctuating cognition | Core feature — early, prominent | Can occur, less prominent | Absent |
| Visuospatial deficits | Early, prominent | Present but secondary | Variable, later |
| Memory | Retrieval > encoding deficit; preserved recognition | Working memory, executive | Encoding deficit; recognition impaired |
| Language | Relatively preserved early | Mild anomia | Progressive anomia |
| Attention | Severe, labile fluctuations | Impaired but more stable | Impaired but stable |
| Feature | DLB | PD | AD |
|---------|-----|----|----|
| Rate of decline | Rapid (median 4-6 years from diagnosis) | Moderate (faster if PDD develops) | Slow-moderate (8-10 years average) |
| Dementia timeline | Cognitive onset simultaneous with or preceding motor | Develops in up to 80% of long-term PD patients | Progressive from memory onset |
| Plateau periods | Uncommon; progressive | Can have plateaus with treatment | Possible brief plateaus |
| End-stage | Severe global impairment, parkinsonism, falls | Severe motor + cognitive | Severe memory, language, behavioral |
The fluctuating cognition in DLB is a cardinal feature driven by the combined loss of cholinergic (nucleus basalis) and noradrenergic (locus coeruleus) inputs to the thalamocortical arousal system[@dupre2024]. This creates moments of near-normal cognition alternating with profound confusion — a phenomenon not seen in AD.
Visual hallucinations in DLB are typically:
| Treatment | DLB | Parkinson's Disease | Alzheimer's Disease |
|-----------|-----|---------------------|---------------------|
| Cholinesterase inhibitors | First-line; often robust response[@bohnen2023] | Modest benefit | First-line; moderate response |
| Memantine | Second-line; used off-label | Not standard | Used in moderate-severe disease |
| Levodopa/Carbidopa | Variable; modest benefit; can worsen hallucinations | First-line; robust benefit | Not applicable |
| Dopamine agonists | Use cautiously; can worsen psychosis | First-line; effective but side effects | Not applicable |
| MAO-B inhibitors | Limited role | First-line adjunct | Not applicable |
| Antipsychotics | AVOID — severe sensitivity, can be fatal | Use cautiously; need PD-specific agents | Use for severe psychosis |
| Pimavanserin | Used off-label for psychosis | FDA-approved for PD psychosis | Not approved |
| RBD treatments | Melatonin, clonazepam | Melatonin, clonazepam | Not typically relevant |
Levodopa is the cornerstone of PD treatment but has limited efficacy in DLB for several reasons:
DLB patients have a profound sensitivity to typical antipsychotics (haloperidol, risperidone, etc.) that can cause:
| Target | DLB | PD | AD |
|--------|-----|----|----|
| Subthalamic nucleus | Not standard | First-line for motor symptoms | Not applicable |
| Globus pallidus interna | Not standard | Used for dyskinesias | Not applicable |
| Nucleus basalis of Meynert | Experimental target for cognition | Investigational | Investigational |
| Pedunculopontine nucleus | Investigational (for RBD/gait) | Investigational | Not applicable |
| Biomarker | DLB | PD | AD | Interpretation |
|-----------|-----|----|----|---------------|
| CSF alpha-synuclein (total) | Reduced | Reduced | Normal | Reflects neuronal loss; not disease-specific |
| CSF alpha-synuclein (phosphorylated, pSer129) | Elevated | Elevated | Normal | Indicates alpha-synuclein pathology |
| RT-QuIC/PMCA seed amplification | ~90% sensitivity/specificity | Positive in majority | Negative | Detects misfolded alpha-synuclein |
| CSF amyloid-beta 42 | Reduced in ~50% (co-pathology) | Normal or reduced | Reduced | Amyloid deposition |
| CSF total tau | Mildly elevated | Normal | Elevated | Neurodegeneration |
| CSF phosphorylated tau (p-tau181, p-tau217) | Mildly elevated (co-pathology) | Normal | Elevated | Tau pathology |
| Neurofilament light chain (NfL) | Elevated | Elevated (less than DLB) | Elevated | General neurodegeneration; DLB > PD > AD |
| Neurogranin | Elevated | Slightly elevated | Elevated | Synaptic dysfunction |
| YKL-40 (neuroinflammation) | Elevated | Elevated | Elevated | Microglial activation |
| Modality | DLB | PD | AD |
|---------|-----|----|----|
| Dopaminergic SPECT/PET (DaTscan) | Reduced striatal binding | Reduced striatal binding | Normal |
| FDG-PET | Posterior cingulate, occipital hypometabolism | Frontal/striatal hypometabolism | Posterior cingulate, medial temporal |
| Amyloid PET (Florbetapir/Flutemetamol) | Positive in ~50% (co-pathology) | Variable | Positive in ~90% |
| Tau PET (Flortaucipir) | Focal uptake in basal ganglia; less than AD | Limited basal ganglia uptake | High cortical uptake, temporal > frontal |
| Structural MRI | Less atrophy than AD; relative preservation of medial temporal | Putaminal iron deposition | Hippocampal and entorhinal atrophy |
| MIBG cardiac scan | Markedly reduced | Reduced | Normal |
| Diffusion MRI | Putaminal diffusion changes | Less prominent | Different pattern |
| MR spectroscopy | Reduced occipital NAA | Variable | Reduced NAA in temporal cortex |
Patient with cognitive decline and/or parkinsonism:
↓
Dopaminergic imaging (DaTscan)?
↓
Reduced → Lewy body disease (DLB or PD)
↓
Amyloid PET / CSF Aβ42?
↓
Positive → DLB + AD co-pathology (mixed dementia)
Negative → DLB (pure) or PD (if motor-first)
↓
Cognitive onset relative to motor symptoms?
↓
Motor first (>1 year) → Parkinson's Disease Dementia
Cognitive simultaneous or first → Dementia with Lewy Bodies
| Gene | DLB | Parkinson's Disease | Alzheimer's Disease |
|------|-----|---------------------|---------------------|
| [SNCA](/genes/snca) (multiplications, point mutations) | Risk factor; A53T causes familial DLB/PD | Major cause of familial PD | Not a direct risk factor |
| [GBA](/genes/gba) (mutations) | Major risk factor; 5-10x increased risk | Major risk factor; 5-10x increased risk | Not a direct risk factor |
| [LRRK2](/genes/lrrk2) (G2019S) | Can cause DLB phenotype[@walker2024] | Most common cause of familial PD | Not a direct risk factor |
| [APOE](/genes/apoe) (ε4 allele) | Modest risk factor | Modest risk factor | Major risk factor (3-4x heterozygote, 10-15x homozygote) |
| [TREM2](/genes/trem2) (risk variants) | Modest effect | Modest effect | 3-fold increased risk |
| SNCAA53T transgenic | Causes familial synucleinopathy | Causes familial PD | Not applicable |
GBA mutations are the strongest genetic link between DLB and PD. The same mutations that increase PD risk by 5-10 fold also increase DLB risk by a similar magnitude, and GBA-associated cases of both diseases share clinical features: earlier onset, faster progression, more prominent cognitive fluctuations.
APOE ε4 has a more modest effect on DLB risk than on AD risk, but the presence of APOE ε4 in DLB increases the likelihood of AD co-pathology and faster decline.
| Target | DLB | PD | AD |
|--------|-----|----|----|
| Alpha-synuclein aggregation | Primary | Primary | Potential (co-pathology) |
| Neuroinflammation | Target | Target | Target |
| Autophagy enhancement | Target | Target | Target |
| Neurotrophic support | Target | Target | Target |
| Synaptic protection | Target | Target | Target |
| Mitochondrial support | Target | Target | Target |
| Dimension | DLB | Parkinson's Disease | Alzheimer's Disease |
|-----------|-----|---------------------|---------------------|
| Primary protein | Alpha-synuclein | Alpha-synuclein | Amyloid-beta + Tau |
| Key pathology | Cortical Lewy bodies | Brainstem Lewy bodies | Plaques + NFTs |
| First symptom | Cognitive/behavioral | Motor (tremor, bradykinesia) | Memory |
| Cholinergic loss | Severe (80-90%) | Moderate | Moderate |
| Dopaminergic loss | Moderate | Severe | Minimal |
| Autonomic dysfunction | Early, severe | Moderate, progressive | Late, mild |
| Visual hallucinations | Early, core feature | Late (drug-induced) | Late, less formed |
| Fluctuating cognition | Prominent | Mild | Absent |
| Levodopa response | Variable | Good-excellent | N/A |
| Cholinesterase response | Robust | Modest | Moderate |
| Disease duration | 4-8 years | 10-20 years | 8-12 years |
| Co-pathology | AD in 50-60% | AD in 40-60% | Alpha-syn in 20-30% |
Related Hypotheses: